-

Catalyst OrthoScience Demonstrates Leadership in Procedural Efficiency with Addition of Fracture to Its Single-Tray Portfolio

Celebrating a decade of innovation, the latest technology expands Catalyst’s efficiency-driven approach to shoulder arthroplasty – making it the first and only company in the industry to offer a single-tray portfolio for anatomic, reverse, and fracture procedures

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the expansion of its single-tray portfolio, with the introduction of a single tray option for the Catalyst Fracture system, at the upcoming Shoulder360™ Annual Meeting. This milestone represents a significant advancement in shoulder surgery workflow efficiency and gives surgeons partnering with Catalyst access to a streamlined, single-tray for every major shoulder arthroplasty case type – stemless anatomic, reverse, and reverse for fracture. Each is designed with predictable layouts, a compact footprint, and fewer instruments to support faster decision-making and lower processing demands, and up to 46% fewer operative steps than competitive systems,1 all without compromising surgical options.

This milestone represents a significant advancement in shoulder surgery workflow efficiency and gives surgeons access to a streamlined, single-tray for every major shoulder arthroplasty case type.

Share

This launch coincides with Catalyst’s celebration of 10 years since the first Catalyst CSR™ implant was used clinically, a defining moment that ignited a new era in shoulder arthroplasty. Since that first case, Catalyst has delivered a continuous stream of meaningful innovation focused on honoring shoulder anatomy and solving clinical and operational challenges that deliver measurable value to surgeons, care teams and facilities. This first decade of advancements for shoulder arthroplasty has been guided by surgeon insight and reinforced by a growing body of published, peer-reviewed clinical evidence. Catalyst will celebrate its first decade of innovation at Shoulder360™ and continue highlighting key milestones throughout 2026 as it accelerates into the next decade of growth.

“We started Catalyst to make shoulder replacement surgery more predictable for surgeons with better outcomes for patients. Ten years and many new products later, the ambition to move our field forward hasn’t changed,” said Dr. Steven Goldberg, orthopedic surgeon at Physicians Regional Healthcare System in Naples, Fla., and founder of Catalyst OrthoScience.

At a time when hospitals and ambulatory surgery centers (ASCs) are under growing pressure to improve efficiency, accelerate case turnover, and control costs, Catalyst is redefining what’s possible - delivering industry-leading, surgeon-first solutions that elevate care for patients and streamline operations for facilities. Anchored by its pioneering single-tray portfolio, Catalyst empowers surgical teams to reduce complexity and instrument burden without sacrificing the flexibility and performance they depend on.

“OR teams face relentless pressure to do more with less, and the traditional way of doing things won’t fix that. Our response is innovation that produces meaningful gains, not incremental tweaks,” said Carl O’Connell, president and chief executive officer at Catalyst. “For 10 years, we’ve challenged outdated approaches and partnered with surgeons to eliminate unnecessary complexity. By reducing tray count, simplifying setup, and creating predictable layouts, the expansion of our single-tray portfolio shows exactly how far that mindset can take us – and we’re just getting started.”

About Catalyst OrthoScience Inc.

Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and based in Naples, Fla., is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Our total shoulder systems are engineered for precision and efficiency – preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the U.S. Learn more at www.catalystortho.com and connect with us on LinkedIn and Instagram.

References

1. Data on file.

Contacts

Nicole Nelson
Media Relations
(239) 325-9976

Catalyst OrthoScience Inc.


Release Versions

Contacts

Nicole Nelson
Media Relations
(239) 325-9976

More News From Catalyst OrthoScience Inc.

Catalyst OrthoScience Announces FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Archer® Patient-Specific Instrumentation (PSI). Licensed in partnership with 3D-Side, Archer PSI is a full suite of humeral and glenoid guides tailored to the patient’s anatomy that allow orthopedic surgeons to execute their 3D p...

Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System

NAPLES, Fla.--(BUSINESS WIRE)--Expanded indications provide surgeons flexibility for better patient outcomes, reinforcing Catalyst’s role as a leader in next-gen shoulder solutions....

Catalyst OrthoScience Secures $15.0 Million in Growth Financing

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the close of $15 million in equity and debt financing, led by RC Capital, with participation from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank, Member FDIC. This latest round of funding strengthens Catalyst’s balance sheet and positions the company to advance its hi...
Back to Newsroom